Scholar Rock Secures Proven FDA Approval for Rare Disease Drug

📰 Curated Industry Article

This is a summary of a full article from a trusted healthcare and insurance publication. Click “Read Full Article” below to read the complete story.

Scholar Rock’s Isembyld isn’t the only FDA-approved therapy for spinal muscular atrophy, but it is the first one that directly targets muscle tissue. Isembyld is the first commercial product for Scholar Rock, which is also evaluating the antibody in other rare muscle disorders.

The post Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease appeared first on MedCity News.

💡 What This Means For You

[armfox_dynamic_insight]

ARMFOX HEALTHCARE

Stay Informed. Protect Your Future.

No pressure. No jargon. Just honest answers from advisors who genuinely care about your family’s protection.

Get a Free Quote →